Sugi Predict

Sugi Predict / Targets / EED

EED

Polycomb protein EED · O75530 · EED on Sugi Atlas →

30,135 patent compounds predicted against EED, 19,124 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL125158 SCHEMBL125158 0.34 10/20
SCHEMBL807423 SCHEMBL807423 0.50 9/20
SCHEMBL123435 SCHEMBL123435 0.35 9/20
SCHEMBL989559 SCHEMBL989559 0.32 8/20
SCHEMBL2586392 SCHEMBL2586392 0.54 7/20
SCHEMBL1695610 SCHEMBL1695610 0.54 7/20
SCHEMBL172472 SCHEMBL172472 0.37 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL125151) 0.36 7/20
SCHEMBL126757 SCHEMBL126757 0.32 7/20
SCHEMBL125753 SCHEMBL125753 0.32 7/20
SCHEMBL1484478 SCHEMBL1484478 0.37 6/20
SCHEMBL124834 SCHEMBL124834 0.36 6/20
SCHEMBL172421 SCHEMBL172421 0.35 6/20
SCHEMBL124483 SCHEMBL124483 0.31 6/20
Tanshinone Iia Tanshinone Iia (SCHEMBL2026738) 1.00 5/20
Tanshinone I Tanshinone I (SCHEMBL728081) 0.73 5/20
SCHEMBL2587354 SCHEMBL2587354 0.68 5/20
SCHEMBL2585411 SCHEMBL2585411 0.68 5/20
SCHEMBL2586263 SCHEMBL2586263 0.62 5/20
SCHEMBL1694628 SCHEMBL1694628 0.53 5/20

Clinical trials — most relevant to EED by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Study of ORIC-944 in Patients With Metastatic Prostate Cancer PHASE1RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
Mechanisms of Immune Deficiency nanUNKNOWN
COPENHAGEN Minipuberty Study nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Exploratory Study of Rectal Mucus for Diagnosing Disease nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Impact of Incomplete Endometrial Ablation nanACTIVE_NOT_RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EED binder may also engage these)

ProteinNameSimilarity
Q921E6 — 1.000 Q921E6 →
Q8UUP2 — 1.000 Q8UUP2 →
Q3SZ25 — 1.000 Q3SZ25 →
Q6AZS2 — 1.000 Q6AZS2 →
Q5ZKH3 — 1.000 Q5ZKH3 →
Q566T0 — 1.000 Q566T0 →
Q28DT7 — 1.000 Q28DT7 →
O16023 — 0.997 O16023 →
Q26458 — 0.997 Q26458 →
Q6DIP5 — 0.996 Q6DIP5 →
Q9LT47 — 0.995 Q9LT47 →
Q24338 — 0.994 Q24338 →
O00423 — 0.992 O00423 →
Q6ZJW8 — 0.992 Q6ZJW8 →
Q20059 — 0.991 Q20059 →
Q6S7B0 — 0.991 Q6S7B0 →
Q3UMY5 — 0.991 Q3UMY5 →
B0X2V9 — 0.991 B0X2V9 →
Q6NQ88 — 0.990 Q6NQ88 →
B4J8H6 — 0.990 B4J8H6 →
Q8VZY7 — 0.990 Q8VZY7 →
Q2TAF3 — 0.989 Q2TAF3 →
Q5F3K4 — 0.989 Q5F3K4 →
Q4R2Z6 — 0.989 Q4R2Z6 →
A6N6J5 — 0.989 A6N6J5 →
B3MET8 — 0.989 B3MET8 →
Q8W117 — 0.989 Q8W117 →
Q16MY0 — 0.989 Q16MY0 →
B4P7H8 — 0.989 B4P7H8 →
Q7ZVA0 — 0.988 Q7ZVA0 →